Charles River Laboratories International, Inc.

New York Stock Exchange
Back to all articles
Bullish +65

Corient Private Wealth LLC Purchases 7,166 Shares of Charles River ...

AI-generated analysis

📈 Corient Private Wealth LLC increased its CRL holdings by 68.5% in Q4, adding 7,166 shares for a total value of $3.5 million.

📊 Institutional ownership stands at 98.91%, with new stakes acquired by Tema ETFs LLC ($26k), Los Angeles Capital Management LLC ($42k), and Sfam LLC ($43k).

📈 Activest Wealth Management saw its stake value increase by 10,900% to $44,000 after purchasing an additional 218 shares.

📈 Barclays raised its price target from $210.00 to $220.00 and maintained an 'overweight' rating on CRL stock.

📈 CLSA upgraded its rating from 'hold' to 'outperform' and increased the price target from $167.00 to $219.00.

📈 Royal Bank of Canada initiated coverage with an 'outperform' rating and a $215.00 price target.

📊 The stock currently trades with a market cap of $10.39 billion and a PEG ratio of 2.46.

📈 Twelve analysts rate the stock as a Buy, while three hold it and one rates it as a Sell.

🏢 CRL provides essential preclinical and clinical support services to accelerate drug development for pharma and biotech clients.

📉 The stock recently opened at $215.68, trading above its 50-day moving average of $176.98.

Bullish Signals
  • Corient Private Wealth LLC significantly increased its position by 68.5% in Q4, adding 7,166 shares to a total holding of 17,628 shares valued at $3.5 million.
  • Multiple institutional investors initiated new positions or increased stakes, including Tema ETFs LLC ($26k), Los Angeles Capital Management LLC ($42k), Sfam LLC ($43k), and Elyxium Wealth LLC ($46k).
  • Activest Wealth Management saw its stake value increase by 10,900% to $44,000 after purchasing an additional 218 shares.
  • Barclays raised its price target from $210.00 to $220.00 and maintained an 'overweight' rating on CRL stock.
  • CLSA upgraded its rating from 'hold' to 'outperform' and increased the price target from $167.00 to $219.00.
  • Royal Bank of Canada initiated coverage with an 'outperform' rating and a $215.00 price target.
  • The consensus analyst rating is 'Moderate Buy' with an average price target of $211.00 based on reports from twelve analysts.
  • Twelve research analysts have assigned a Buy rating to the stock, indicating strong institutional confidence in its growth prospects.
Full Analysis
Corient Private Wealth LLC significantly increased its position in Charles River Laboratories International (NYSE:CRL) by 68.5% during the fourth quarter, adding 7,166 shares to a total holding of 17,628 shares valued at $3.5 million. Several other institutional investors also entered new positions or increased stakes, including Tema ETFs LLC, Los Angeles Capital Management LLC, and Sfam LLC, while Activest Wealth Management saw its stake value jump by 10,900% to $44,000. Analyst sentiment for CRL remains generally positive with a consensus 'Moderate Buy' rating and an average price target of $211.00. Recent upgrades include Barclays raising its target to $220.00 with an 'overweight' rating, CLSA upgrading from 'hold' to 'outperform' with a target of $219.00, and Royal Bank of Canada initiating coverage with an 'outperform' rating at $215.00. Charles River Laboratories International operates as a leading provider of research models and preclinical support services for the pharmaceutical and biotechnology sectors. Founded in 1947, the company offers discovery, safety assessment, toxicology, and pathology services alongside laboratory animal supply to help clients accelerate drug development from early discovery through regulatory submission.